Clinical Trials Browser

Phase 1/2 × loncastuximab tesirine × 90 days × Clear all

NCT05658562 2026-02-13

A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

Phase 1/2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse